The Supremes Shape Pharma

Wechsler, Jill
August 2011
Pharmaceutical Representative;Aug2011, Vol. 41 Issue 8, p32
The article focuses on the possible effects of Supreme Court decisions on the U.S. pharmaceutical industry. According to the author, several Supreme Court decisions are likely to affect the industry particularly in drug marketing, research and regulation. She adds that much debate has been made on the Court's opinion on the free speech rights of physicians data.


Related Articles

  • TALKING DRUGS: THE BURDENS OF PROOF IN POST-GARCETTI SPEECH RETALIATION CLAIMS. Hudson, Thomas E. // Washington Law Review;Oct2012, Vol. 87 Issue 3, p777 

    Law Enforcement agencies fire their employees for speaking out in favor of drug legalization, which leads the employees to sue their former employers for violating their First Amendment Free Speech rights. These employee claims fall under the U.S. Supreme Court's complex speech retaliation test,...

  • Ned's December pick: Case of the year. Milenkovich, Ned // Drug Topics;Dec2011, Vol. 155 Issue 12, p60 

    The article reports that the U.S. Supreme Court opted against a Vermont law related to marketing of drugs in the court case Sorrell v. IMS Health Inc. It states that the law restricted marketing of drugs to prescribers if advertising was based on history of writing drug prescriptions. The court...

  • Court: Drug Detailing is Free Speech.  // BioWorld Today;6/27/2011, Vol. 22 Issue 123, p8 

    The article focuses on a U.S. Supreme Court ruling in June 2011 which rejected a Vermont law that bans the commercial use of prescriber-identifiable data and affirmed biopharmaceutical industry's free speech.

  • The Court vs. the Reformers. Will, George F. // Newsweek;12/13/2010, Vol. 156 Issue 24, p26 

    The article discusses the constitutional right to free political speech in the U.S. Special attention is paid to an Arizona law described by the author that seems to favor publicly-funded political candidates in that state over privately-funded ones. The law is being challenged, and in the...

  • OF, BY AND FOR THE PEOPLE, NOT THE CORPORATIONS.  // Syracuse New Times;7/2/2014, Issue 3480, p46 

    The article focuses on the enforcement of the freedom of speech by the U.S. Supreme Court under the First Amendment.

  • Support grows for pharmacist provider status bill.  // Chain Drug Review;4/18/2016, Vol. 38 Issue 7, p67 

    The article discusses the enactment of the Ensuring Seniors Access to Local Pharmacies Act of 2015 for the pharmaceutical sector in the U.S.

  • Drug Postmarketing Studies. Kashoki, Mwango; Lee, Cathryn; Jenkins, John // JAMA: Journal of the American Medical Association;12/11/2013, Vol. 310 Issue 22, p2459 

    A letter to the editor is presented in response to the research letter "The Food and Drug Administration Amendments Act and Postmarketing Commitments" by Kevin Fain et al. in a 2013 issue.

  • Drug Postmarketing Studies. Fain, Kevin; Alexander, G. Caleb // JAMA: Journal of the American Medical Association;12/11/2013, Vol. 310 Issue 22, p2459 

    A response by Kevin Fain and G. Caleb Alexander to a letter to the editor about their research letter "The Food and Drug Administration Amendments Act and Postmarketing Commitments" in a 2013 issue is presented.

  • Supreme Court Denies Review of State Law Restricting Data-Mining.  // Journal of AHIMA;2009, Vol. 80 Issue 8, p12 

    The article reports that the U.S. Supreme Court has refused to hear an appeal by health data-mining firms, that would reportedly block a New Hampshire law restricting the use of information related to physicians' prescribing habits. The New Hampshire law was passed in 2006, which reportedly made...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics